文献速递贫血与红细胞疾病造血干细胞移植与细胞治疗

成人再生障碍性贫血患者的临床结局:单中心经验

Clinical outcomes in adult patients with aplastic anemia: A single institution experience.
PubMed 文献 · Am J Hematol · 2017-09-25

该单中心研究回顾了126例成人再生障碍性贫血患者,其中初治95例、复发/难治63例(含32例来自初治队列),分析以抗胸腺球蛋白为基础的联合免疫抑制方案在前线及复发/难治中的结局。免疫抑制治疗应答者总生存更优(P < .001),部分应答较完全应答无复发生存更短(P = .03);基线血小板和淋巴细胞分别预测3个月和6个月应答;不同前线方案间无复发生存或总生存无统计学显著差异。

要点

  • 免疫抑制治疗应答者总生存优于未应答者(P < .001)。
  • 部分应答较完全应答无复发生存更短(P = .03)。
  • 基线血小板和淋巴细胞分别预测3个月和6个月免疫抑制治疗应答。

核心结论

  • 免疫抑制治疗应答者总生存更优(P < .001),部分应答较完全应答无复发生存更短(P = .03)。
  • 不同前线免疫抑制方案(含或不含G-CSF或艾曲泊帕)间无复发生存或总生存无统计学显著差异。
  • 挽救性免疫抑制治疗应答取决于既往对ATG的应答:既往应答者46% vs 原发难治者0%(P < .01)。

研究设计与样本

  • 单中心回顾性分析成人再生障碍性贫血患者,共126例,其中初治95例、复发/难治63例(含32例来自初治队列)。
  • 初治和复发/难治队列中位年龄分别为49岁和50岁。
  • 分析治疗前及治疗中临床特征与应答和结局的关系。

主要发现

  • 免疫抑制治疗应答者总生存优于未应答者(P < .001)。
  • 部分应答较完全应答无复发生存更短(P = .03)。
  • 多因素分析显示基线血小板和淋巴细胞分别预测3个月和6个月免疫抑制治疗应答。
  • 额外生长因子干预使血细胞计数恢复更快,但不同前线免疫抑制方案间无复发生存或总生存无统计学显著差异。
  • 骨髓细胞面积与3个月外周血计数不相关;细胞形态学评估显示所有非应答者伴骨髓细胞增多指数者存在发育异常改变。

关键数值与推荐

  • 挽救性免疫抑制治疗应答:既往对ATG应答者46% vs 原发难治者0%(P < .01)。
  • 复发/难治设置中免疫抑制治疗与异基因造血干细胞移植组间无生存差异,前者总生存有更优趋势。
  • 早期骨髓评估发现的隐匿性发育异常对免疫抑制治疗失败后治疗选择有影响。

临床怎么用

  • 免疫抑制治疗应答者总生存更优(P < .001)。
  • 不同前线免疫抑制方案(含或不含G-CSF或艾曲泊帕)间无复发生存或总生存无统计学显著差异。
  • 复发/难治设置中免疫抑制治疗与异基因造血干细胞移植组间无生存差异,前者总生存有更优趋势;移植获益可能因移植相关死亡而未充分实现。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Newer treatment modalities are being investigated to improve upon historical outcomes with standard immunosuppressive therapy (IST) in aplastic anemia (AA). We analyzed outcomes of adult patients with AA treated with various combinatorial anti-thymoglobulin-based IST regimens in frontline and relapsed/refractory (R/R) settings. Pretreatment and on-treatment clinical characteristics were analyzed for relationships to response and outcome. Among 126 patients reviewed, 95 were treatment-naïve (TN) and 63, R/R (including 32 from the TN cohort); median ages were 49 and 50 years, respectively. Overall survival (OS) was superior in IST responders (P < .001). Partial response to IST was associated with shorter relapse-free survival (RFS), as compared with complete response (P = .03). By multivariate analysis, baseline platelet and lymphocyte count predicted for IST response at 3 and 6 months, respectively. While additional growth factor interventions led to faster count recovery, there were no statistically significant differences in RFS or OS across the various frontline IST regimens (i.e., with/without G-CSF or eltrombopag). While marrow cellularity did not correlate with peripheral-blood counts at 3 months, cytomorphological assessment revealed dyspoietic changes in all nonresponders with hypercellular-marrow indices. Covert dysplasia, identified through early bone marrow assessment, has implications on future therapy choices after IST failure. Salvage IST response depended upon prior response to ATG: prior responders (46%) vs. primary refractory (0%) (P < .01). In the R/R setting, there was no survival difference between IST and allogeneic stem cell transplant groups, with a trend toward superior OS in the former. Transplant benefits in the R/R setting may be underrealized due to transplant-related mortality.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Boddu P, Garcia-Manero G, Ravandi F, et al. Clinical outcomes in adult patients with aplastic anemia: A single institution experience. Am J Hematol. 2017. PMID: 28850699. doi:10.1002/ajh.24897

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。